Treatment of testicular germ-cell cancer: a cochrane evidence-based systematic review.
Testicular germ-cell cancer is relatively rare, affecting less than 6 men per 100,000 in the UK, nevertheless, it is the most common cancer in men under 45 years. The two main types of tumours, seminomas and non-seminomas, respond to treatment differently. The standard treatment for stage I seminomas following orchidectomy is infradiaphragmatic lymph node irradiation with response rates approaching 100%, although surveillance is also a management option. The majority of early stage non-seminomas are cured by orchidedctomy alone. Bleomycin, etoposide and cisplatin, (BEP) is the most widely used chemotherapeutic regimen for metastatic germ cell tumours. In patients with 'good prognosis' the current focus is to reduce the drug-related toxicity but maintain the cure potential. Most attempts using dose reduction or alternative regimens have not proved superior to BEP. In patients with 'poor prognosis' the aim has been to increase the efficacy of treatment using high-dose chemotherapy and investigate new regimens. This article comprehensively reviews the treatment of testicular germ cell cancer with emphasis on high-grade evidence from randomised controlled trials.
Shelley
M D
MD
Cochrane Unit, Research Department, Cardiff, Wales, UK. mike.shelley@velindre-tr.wales.nhs.uk
Burgon
K
K
Mason
M D
MD
D000970:Antineoplastic Agents / Q000627:therapeutic use*; D019317:Evidence-Based Medicine; D018237:Germinoma / Q000188:drug therapy*; D006801:Humans; D008297:Male; D016032:Randomized Controlled Trials as Topic; D013736:Testicular Neoplasms / Q000188:drug therapy*
D000970:Antineoplastic Agents